New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
07:31 EDTFOLDAmicus Theraputics weakness a buying opportunity, says JPMorgan
JPMorgan views the pullback in shares of Amicus Theraputics on the company's Phase 3 trial miss as a buying opportunity. The firm says migalastat is active in Fabry and safe, and reiterates an Overweight rating on the stock, despite lowering its price target for shares to $5 from $9.
News For FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
07:32 EDTFOLDAmicus Therapeutics to submit EU MAA for migalastat HCl
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use